BCLI — Brainstorm Cell Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $6.74m
- $6.02m
Annual balance sheet for Brainstorm Cell Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 41.9 | 22.1 | 2.98 | 1.3 | 0.187 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.304 | 0.086 | 0.091 | 0.051 | 0.063 |
| Prepaid Expenses | |||||
| Total Current Assets | 43.2 | 23.3 | 3.11 | 1.9 | 0.385 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 7.99 | 5.97 | 5.32 | 2.1 | 1.24 |
| Other Long Term Assets | |||||
| Total Assets | 51.3 | 29.3 | 8.45 | 4.21 | 1.83 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.2 | 6.32 | 8.8 | 7.8 | 8.98 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 15.8 | 9.94 | 11.5 | 9.07 | 9.6 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 35.5 | 19.3 | -3.02 | -4.86 | -7.76 |
| Total Liabilities & Shareholders' Equity | 51.3 | 29.3 | 8.45 | 4.21 | 1.83 |
| Total Common Shares Outstanding |